Nebenwirkungen · Lucentis
Lucentis 10 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-116986 · Präparat HOS-094515
In the wet AMD phase III studies, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in ranibizumab-treated patients. However, there was no consistent pattern among the different haemorrhages. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the Lucentis clinical studies in patients with AMD, DME, PDR, RVO and CNV and there were no major differences between the groups treated with ranibizumab compared to control.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:52:00Z · SHA-256 99f5c71aa34ea0289059cf6afa389329036ec0035d42e5a4cfeaefbb65a1300c · Passage f342064f06795b8a01ea7fcb4c46ae23d3062d009b07f1e7f8494d3e8c161130 · Zeichen 4742–5459 im Abschnitt